Atlas FDA

ACCESS HYBRITECH P2PSA REAGENTS ON THE ACCESS IMMUNOASSAY SYSTEMS

FDA premarket approval P090026/S015 · decided 2015-06-23

Approval details

PMA number
P090026
Supplement
S015
Supplement type
Real-Time Process
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
ACCESS HYBRITECH P2PSA REAGENTS ON THE ACCESS IMMUNOASSAY SYSTEMS
Generic name
P2psa
Applicant
Beckman Coulter, Inc.
Date received
2015-05-07
Decision date
2015-06-23
Days to decision
47 days
Decision code
APPR
Product code
OYA
Advisory committee
Immunology
Expedited review
No
Location
Chaska, MN
Statement
APPROVAL FOR LABELING CHANGES TO ALIGN WITH GLOBALLY HARMONIZEDSYSTEM OF CLASSIFICATION OF CHEMICALS (GHS) WHICH PROVIDES A CONSISTENT HAZARD CLASSIFICATION SYSTEM THAT IS RECOGNIZED GLOBALLY.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Access BNP II (K252169)Beckman Coulter, Inc.2026-03-24
Access anti-HBc IgM (K254059)Beckman Coulter, Inc.2026-03-13
Access anti-HBc Total (K253687)Beckman Coulter, Inc.2026-02-19
Access anti-HAV IgM (K251995)Beckman Coulter, Inc.2026-01-27
Access Rubella IgG (K250588)Beckman Coulter, Inc.2025-11-17
iQ200 Series (K252580)Beckman Coulter, Inc.2025-09-10
Access anti-HAV (K243846)Beckman Coulter, Inc.2025-09-09
MicroScan Dried Gram-Negative MIC/Combo Panels with Cefepime (CPE) (0.12-64 µg/mL) (MicroScan) (K243804)Beckman Coulter, Inc.2025-08-20